NVCR News and Press, NovoCure Limited From 07/22/23

2023-07-22 05:30:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Economic resiliency, s...

Pre-specified interim analysis concluded that the fully enrolled PANOVA-3 clinical trial should proceed to final analysis as planned Novocure (NASDAQ: NVCR) today announced the results of a pre-specified interim analysis for the phase 3 PANOVA-3 clinical trial evaluating the safety and ...

MOORE KUEHN ANNOUNCES ENCOURAGES NOVOCURE LIMITED INVESTORS TO CONTACT LAW FIRM PR Newswire NEW YORK , July 14, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a securities and shareholder law firm located on Wall Street, is investigating potential claims against: ...

NEW YORK, NY / ACCESSWIRE / July 10, 2023 / Levi & Korsinsky, LLP notifies investors in NovoCure Limited ("NovoCure" or the "Company") (NASDAQ:NVCR) of a class action securities lawsuit. The lawsuit on behalf of NovoCure investors has been commenced in the United States District Court for...

2023-07-06 13:17:16 ET Novocure (NASDAQ: NVCR) shares dropped after publishing the results of an important clinical trial. The headlines looked positive at first glance, but the study raised concerns that lung cancer treatment might not have a place in the market. As a result, the s...

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2023 on Thursday, July 27, 2023, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three...

2023-06-13 23:49:18 ET Summary NovoCure's Tumor Treating Fields (TTFields) technology is seeking FDA approval for use in non-small cell lung cancer (NSCLC), despite the company's recent stock decline. The Q1 2023 financial report shows decreased net revenues and increased expenses...

2023-06-12 05:39:00 ET These days, investors can find plenty of reasons to feel nervous about buying stocks. Surging inflation, soaring interest rates, and geopolitical tensions are all legitimate concerns for most businesses. In these challenging times, investors would do well to remem...

2023-06-07 08:38:13 ET NovoCure Limited ( NASDAQ: NVCR ) eked out a ~3% gain in the pre-market Wednesday as Wedbush upgraded the medical device maker to Neutral from Underperform, citing a favorable risk-reward setup following a ~43% slump in the previous session. Reviewing ...

2023-06-07 06:21:00 ET Stock index futures were slightly lower, with investors still reluctant to commit to a firm direction a week before CPI and the Fed. S&P futures ( SPX ) -0.1% , Dow futures ( INDU ) -0.2% and Nasdaq 100 futures ( NDX:IND ) -0.1% wer...